FY2017 EPS Estimates for Teleflex Incorporated (TFX) Increased by Analyst

Teleflex Incorporated (NYSE:TFX) – Investment analysts at KeyCorp raised their FY2017 earnings estimates for Teleflex in a note issued to investors on Thursday. KeyCorp analyst M. Mishan now forecasts that the medical technology company will post earnings of $8.34 per share for the year, up from their prior forecast of $8.30. KeyCorp has a “Hold” rating on the stock. KeyCorp also issued estimates for Teleflex’s FY2018 earnings at $9.70 EPS and FY2019 earnings at $11.18 EPS.

Several other brokerages have also issued reports on TFX. Zacks Investment Research lowered Teleflex from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Stephens reaffirmed a “buy” rating and issued a $270.00 target price (up previously from $230.00) on shares of Teleflex in a research note on Monday, September 25th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $251.00 target price (up previously from $238.00) on shares of Teleflex in a research note on Monday, September 18th. Barclays PLC reaffirmed an “overweight” rating and issued a $253.00 target price (up previously from $230.00) on shares of Teleflex in a research note on Tuesday, September 12th. Finally, Leerink Swann raised Teleflex from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $227.00 to $266.00 in a research note on Thursday, September 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $260.75.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://ledgergazette.com/2017/10/16/fy2017-eps-estimates-for-teleflex-incorporated-tfx-increased-by-analyst.html.

Shares of Teleflex (TFX) opened at 238.71 on Monday. Teleflex has a 52 week low of $136.53 and a 52 week high of $248.68. The firm has a market cap of $10.75 billion, a price-to-earnings ratio of 45.65 and a beta of 1.07. The firm has a 50 day moving average of $233.66 and a 200 day moving average of $211.26.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.91 by $0.13. Teleflex had a net margin of 12.36% and a return on equity of 16.12%. The company had revenue of $528.60 million for the quarter, compared to analyst estimates of $518.98 million. During the same quarter last year, the business earned $1.89 earnings per share. Teleflex’s revenue was up 11.6% compared to the same quarter last year.

Several large investors have recently added to or reduced their stakes in TFX. Janus Henderson Group PLC boosted its stake in shares of Teleflex by 50,429.2% during the second quarter. Janus Henderson Group PLC now owns 1,816,020 shares of the medical technology company’s stock valued at $377,296,000 after purchasing an additional 1,812,426 shares during the period. Koch Industries Inc. raised its holdings in shares of Teleflex by 47,174.3% during the second quarter. Koch Industries Inc. now owns 959,669 shares of the medical technology company’s stock valued at $955,000 after acquiring an additional 957,639 shares in the last quarter. Marshall Wace North America L.P. raised its holdings in shares of Teleflex by 137.4% during the second quarter. Marshall Wace North America L.P. now owns 518,462 shares of the medical technology company’s stock valued at $107,840,000 after acquiring an additional 300,069 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Teleflex by 93.5% during the second quarter. Principal Financial Group Inc. now owns 610,398 shares of the medical technology company’s stock valued at $126,816,000 after acquiring an additional 294,935 shares in the last quarter. Finally, FMR LLC raised its holdings in shares of Teleflex by 46.5% during the first quarter. FMR LLC now owns 811,764 shares of the medical technology company’s stock valued at $157,263,000 after acquiring an additional 257,649 shares in the last quarter. 89.75% of the stock is owned by hedge funds and other institutional investors.

In other news, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $211.75, for a total transaction of $42,350.00. Following the completion of the sale, the director now owns 8,080 shares of the company’s stock, valued at $1,710,940. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 600 shares of company stock valued at $132,408. Insiders own 2.39% of the company’s stock.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and

Teleflex Incorporated (NYSE:TFX) – Investment analysts at KeyCorp raised their FY2017 earnings estimates for Teleflex in a note issued to investors on Thursday. KeyCorp analyst M. Mishan now forecasts that the medical technology company will post earnings of $8.34 per share for the year, up from their prior forecast of $8.30. KeyCorp has a “Hold” rating on the stock. KeyCorp also issued estimates for Teleflex’s FY2018 earnings at $9.70 EPS and FY2019 earnings at $11.18 EPS.

Several other brokerages have also issued reports on TFX. Zacks Investment Research lowered Teleflex from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Stephens reaffirmed a “buy” rating and issued a $270.00 target price (up previously from $230.00) on shares of Teleflex in a research note on Monday, September 25th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $251.00 target price (up previously from $238.00) on shares of Teleflex in a research note on Monday, September 18th. Barclays PLC reaffirmed an “overweight” rating and issued a $253.00 target price (up previously from $230.00) on shares of Teleflex in a research note on Tuesday, September 12th. Finally, Leerink Swann raised Teleflex from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $227.00 to $266.00 in a research note on Thursday, September 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $260.75.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://ledgergazette.com/2017/10/16/fy2017-eps-estimates-for-teleflex-incorporated-tfx-increased-by-analyst.html.

Shares of Teleflex (TFX) opened at 238.71 on Monday. Teleflex has a 52 week low of $136.53 and a 52 week high of $248.68. The firm has a market cap of $10.75 billion, a price-to-earnings ratio of 45.65 and a beta of 1.07. The firm has a 50 day moving average of $233.66 and a 200 day moving average of $211.26.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.91 by $0.13. Teleflex had a net margin of 12.36% and a return on equity of 16.12%. The company had revenue of $528.60 million for the quarter, compared to analyst estimates of $518.98 million. During the same quarter last year, the business earned $1.89 earnings per share. Teleflex’s revenue was up 11.6% compared to the same quarter last year.

Several large investors have recently added to or reduced their stakes in TFX. Janus Henderson Group PLC boosted its stake in shares of Teleflex by 50,429.2% during the second quarter. Janus Henderson Group PLC now owns 1,816,020 shares of the medical technology company’s stock valued at $377,296,000 after purchasing an additional 1,812,426 shares during the period. Koch Industries Inc. raised its holdings in shares of Teleflex by 47,174.3% during the second quarter. Koch Industries Inc. now owns 959,669 shares of the medical technology company’s stock valued at $955,000 after acquiring an additional 957,639 shares in the last quarter. Marshall Wace North America L.P. raised its holdings in shares of Teleflex by 137.4% during the second quarter. Marshall Wace North America L.P. now owns 518,462 shares of the medical technology company’s stock valued at $107,840,000 after acquiring an additional 300,069 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Teleflex by 93.5% during the second quarter. Principal Financial Group Inc. now owns 610,398 shares of the medical technology company’s stock valued at $126,816,000 after acquiring an additional 294,935 shares in the last quarter. Finally, FMR LLC raised its holdings in shares of Teleflex by 46.5% during the first quarter. FMR LLC now owns 811,764 shares of the medical technology company’s stock valued at $157,263,000 after acquiring an additional 257,649 shares in the last quarter. 89.75% of the stock is owned by hedge funds and other institutional investors.

In other news, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $211.75, for a total transaction of $42,350.00. Following the completion of the sale, the director now owns 8,080 shares of the company’s stock, valued at $1,710,940. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 600 shares of company stock valued at $132,408. Insiders own 2.39% of the company’s stock.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply